Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Resident Kupffer cells and neutrophils drive liver toxicity in cancer immunotherapy

ABSTRACT: Resident Kupffer cells and neutrophils drive liver toxicity in cancer immunotherapy

PROVIDER: PRJNA733462 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR14676727.fastq.gz	Fastqsanger.gz
	SRR14676728.fastq.gz	Fastqsanger.gz
	SRR14676729.fastq.gz	Fastqsanger.gz
	SRR14676730.fastq.gz	Fastqsanger.gz
	SRR14676731.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 16

Similar Datasets

Resident Kupffer cells and neutrophils drive liver toxicity in cancer immunotherapy

Project description:Immunotherapy is revolutionizing cancer treatment but can trigger toxicities that remain poorly understood. Here, by comprehensively analyzing mouse models following anti-CD40 therapy, we found an interdependent induction of the cytokines IFN-g and IL-12, which caused inflammatory pathology in various tumor-free tissues. In the liver, Kupffer cells mediated toxicity by sensing lymphocyte-derived IFN-g and producing IL-12, highlighting the vulnerability of tissue-resident macrophages to promote toxicity when reacting to proinflammatory cues. Conversely, dendritic cells drove tumor control but were dispensable for toxicity. We further show that liver macrophages, IL-12, and IFN-g were not toxic themselves, but prompted a neutrophil response that determined the severity of tissue damage. Similar inflammatory pathways characterized immunotherapy-related adverse events in cancer patients. These findings implicate resident macrophages and neutrophils as mediators and effectors of aberrant inflammation, and suggest distinct cellular mechanisms of toxicity and antitumor immunity.

2021-06-03 | GSE175737 | GEO

Resident Kupffer cells and neutrophils drive liver toxicity in cancer immunotherapy

Project description:Immunotherapy is revolutionizing cancer treatment, but is often restricted by toxicities. What distinguishes adverse events from concomitant antitumor reactions remains poorly understood. Here, using anti-CD40-treatment in mice as a model of Th1-promoting immunotherapy, we show liver macrophages’ vulnerability to promote local adverse events. Mechanistically, tissue-resident Kupffer cells mediate liver toxicity by sensing lymphocyte-derived IFN-g and producing IL-12. Conversely, dendritic cells are dispensable for toxicity but drive tumor control. Though macrophages, IL-12, and IFN-g are not necessarily toxic themselves, we find that they prompt a neutrophil response that determines the severity of tissue damage. We further show that similar inflammatory pathways characterize adverse events across tissues, following anti-PD-1 and anti-CTLA4 immunotherapies, and in humans. These findings implicate macrophages and neutrophils as mediators and effectors of aberrant inflammation in Th1-promoting immunotherapy, and suggest distinct mechanisms of toxicity and antitumor immunity.

2021-06-04 | GSE176109 | GEO

Resident Kupffer cells and neutrophils drive liver toxicity in cancer immunotherapy

Project description:Resident Kupffer cells and neutrophils drive liver toxicity in cancer immunotherapy

| PRJNA734933 | ENA

Resident Kupffer cells and neutrophils drive liver toxicity in cancer immunotherapy.

Project description:Immunotherapy is revolutionizing cancer treatment but is often restricted by toxicities. What distinguishes adverse events from concomitant antitumor reactions is poorly understood. Here, using anti-CD40 treatment in mice as a model of TH1-promoting immunotherapy, we showed that liver macrophages promoted local immune-related adverse events. Mechanistically, tissue-resident Kupffer cells mediated liver toxicity by sensing lymphocyte-derived IFN-γ and subsequently producing IL-12. Conversely, dendritic cells were dispensable for toxicity but drove tumor control. IL-12 and IFN-γ were not toxic themselves but prompted a neutrophil response that determined the severity of tissue damage. We observed activation of similar inflammatory pathways after anti-PD-1 and anti-CTLA-4 immunotherapies in mice and humans. These findings implicated macrophages and neutrophils as mediators and effectors of aberrant inflammation in TH1-promoting immunotherapy, suggesting distinct mechanisms of toxicity and antitumor immunity.

| S-EPMC8845079 | biostudies-literature

Targeted erythrophagocyte reprogramming of Kupffer cells halts cancer immunotherapy associated liver toxicity

Project description:Targeted erythrophagocyte reprogramming of Kupffer cells halts cancer immunotherapy associated liver toxicity

| PRJNA837625 | ENA

Targeted erythrophagocyte reprogramming of Kupffer cells halts cancer immunotherapy associated liver toxicity [Multiplexed_CD40]

Project description:Targeted erythrophagocyte reprogramming of Kupffer cells halts cancer immunotherapy associated liver toxicity [Multiplexed_CD40]

| PRJNA837628 | ENA

Targeted erythrophagocyte reprogramming of Kupffer cells halts cancer immunotherapy associated liver toxicity [Ter119 experiment]

Project description:Targeted erythrophagocyte reprogramming of Kupffer cells halts cancer immunotherapy associated liver toxicity [Ter119 experiment]

| PRJNA837627 | ENA

Faecalibacterium prausnitzii abrogates immunotherapy toxicity

Project description:Faecalibacterium prausnitzii abrogates immunotherapy toxicity

| PRJNA932844 | ENA

Gene expression in inflammatory macrophages, tissue resident macrophages and neutrophils

Project description:Genes expression in Ly6C+/F4/80+ inflammatory macrophages, CX3CR1+/F4/80+ tissue resident macrophages and Ly6G+/F4/80- neutrophils which were isolated from day 3 wounds in C57/B6 mice aged 8 weeks by cell sorting Ly6C+ macrophages expressed higher (over 5 folds) levels of 241 genes compared to CX3CR1+ macrophages, and 3382 genes compared to neutrophils

2016-07-01 | E-GEOD-74783 | biostudies-arrayexpress

ATAC-seq of tissue resident neutrophils

Project description:ATAC-seq of tissue resident neutrophils

| PRJNA593008 | ENA